NSI-189磷酸盐治疗重性抑郁障碍的2期双盲安慰剂对照研究
主要结局MADRS评分改善未达显著,但40 mg剂量在SDQ、CPFQ及SPCD第二阶段QIDS-SR上优于安慰剂,部分CogScreen客观认知指标也显示优势,两种剂量耐受性良好。
要点
- NSI-189 40 mg和80 mg每日治疗12周,MADRS评分改善均未显著优于安慰剂。
- 40 mg剂量在SDQ、CPFQ及SPCD第二阶段QIDS-SR上显示优于安慰剂的改善。
- 40 mg剂量在部分CogScreen客观认知指标上显示优势,但Cogstate测试未见优势。
核心结论
- NSI-189 40 mg和80 mg每日治疗12周对MADRS评分改善未显著优于安慰剂,但40 mg在部分患者自评和认知指标上显示优势,耐受性良好。
主要发现
- MADRS评分较安慰剂的降低未达显著性:40 mg合并均差-1.8(p=0.22),80 mg合并均差-1.4(p=0.34)。
- 40 mg剂量SDQ合并均差-8.2(Stage 1和2的Cohen's d分别为-0.11和-0.64,p=0.04),CPFQ合并均差-1.9(Cohen's d分别为-0.28和-0.47,p=0.03)。
- 40 mg剂量在SPCD第二阶段QIDS-SR评分上均差-2.5(Cohen's d Stage 1和2分别为-0.03和-0.68,p=0.04)。
- 40 mg剂量在部分CogScreen客观认知指标上显示优势(绝对Cohen's d范围0.12至1.12,有利NSI-189,总体显著者p值0.002至0.048),但Cogstate测试未见优势。
- 两种剂量均耐受性良好。
临床怎么用
- 目前证据尚不支持NSI-189作为重性抑郁障碍的单药治疗用于临床实践,需进一步研究验证其抗抑郁和促认知效应。
局限性
- 主要结局MADRS未达显著,阳性结果仅限于部分次要指标,且研究采用SPCD设计可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks. The primary outcome measure was the Montogmery Asberg Depression Rating Scale (MADRS). Secondary subject-rated measures included the Symptoms of Depression Questionnaire (SDQ), the Cognitive and Physical Functioning Scale (CPFQ), the patient-rated version of the Quick Inventory of Depressive Symptomatology Scale (QIDS-SR), and subtests from the CogScreen and Cogstate cognitive tests. MADRS score reduction versus placebo did not reach significance for either dose (40 mg pooled mean difference -1.8, p = 0.22, 80 mg pooled mean difference -1.4, p = 0.34, respectively). However, the 40 mg dose showed greater overall reduction in SDQ (pooled mean difference -8.2; Cohen's d for Stages 1 and 2 = -0.11 and -0.64, p = 0.04), and CPFQ scores (pooled mean difference -1.9; Cohen's d for Stages 1 and 2 = -0.28 and -0.47, p = 0.03) versus placebo, as well as QIDS-SR scores in Stage 2 of SPCD (-2.5; Cohen's d Stages 1 and 2 = -0.03 and -0.68, p = 0.04). The 40 mg dose also showed advantages on some objective cognitive measures of the CogScreen (absolute Cohen's d ranged between 0.12 and 1.12 in favor of NSI-189, p values between 0.002 and 0.048 for those with overall significance), but not the Cogstate test. Both doses were well tolerated. These findings replicate those of phase 1b study, and warrant further exploration of the antidepressant and pro-cognitive effects of NSI-189.
引用
- Papakostas GI, Johe K, Hand H, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2019. PMID: 30626911. doi:10.1038/s41380-018-0334-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。